UmanDiagnostics was founded in 2006 by Niklas Norgren and Torgny Stigbrand and is located at the Umeå Biotech Incubator. From the outset the company has worked with nerve injury markers and the protein NF-light. NF-light is found in nerve cells and if nerves become damaged due to a trauma or neurological disease the protein leaks into the cells’ surroundings. Thanks to UmanDiagnostics’ nerve marker a simple blood test measures how much of the NF-light protein has leaked out, which helps indicate how significant any damage may be.
At the end of June 2019 UmanDiagnostics was purchased by its largest customer and partner – US life science tools company Quanterix. Thanks to the acquisition UmanDiagnostics gained access to Quanterix’s marketing and sales department, which resulted in two new appointments being made at the company’s Umeå offices.
The two new employees are Charlotta Norman, who will focus on customer support, orders and logistics, and Carola Falk, who will work with research and development.
“We are very happy to have them both join us. Now we are an even bigger team working to improve the living conditions of patients with neurological disorders”, says Niklas Norgren.
As part of acquisition negotiations it was agreed UmanDiagnostics would retain its name and remain in Umeå.
“That’s why it feels extra rewarding that even at this early stage we can hire new employees. There is huge demand for neurodiagnostic products and with our expanded marketing channels we can now reach an even larger target group of potential customers. We will almost certainly need to hire even more people in the future”, says Niklas Norgren.
The two new appointments brings the total number of staff at UmanDiagnostics to eight.
UmanDiagnostics has been nominated for Technology Award of the Year and Spin-Off Company of the Year at Umeågalan 2019.
For more information, please contact:
Niklas Norgren, CEO at UmanDiagnostics
090-77 78 80
UmanDiagnostics is committed to delivering fast and accurate diagnosis of neurological diseases. The company develops and markets valuable tools for early detection of diseases, measuring treatment efficacy and monitoring of disease progression. The company was founded in 2006 and since then has focussed on diseases affecting white matter such as Multiple Sclerosis, Alzheimer’s Disease and Amyotrophic Lateral Sclerosis.